PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction with IC50 value of 6 nM. PD1-PDL1 inhibitor is also an immunomodulator. PD-L1 also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene. It appears that upregulation of PD-L1 may allow cancers to evade the host immune system.
J Allergy Clin Immunol. 2020 Mar;145(3):855-867.e8.
Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis.
PD1-PDL1 inhibitor 1 purchased from AbMole
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO: ≥ 60 mg/mL|
Inhibition of programmed death-1 decreases neointimal hyperplasia after patch angioplasty
Hualong Bai, et al. J Biomed Mater Res B Appl Biomater. 2021 Feb;109(2):269-278. PMID: 32770622.
The future of immunotherapy for sarcoma.
Tsukahara T, et al. Expert Opin Biol Ther. 2016 Aug;16(8):1049-57. PMID: 27158940.
Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.
Ngiow SF, et al. Oncoimmunology. 2015 Dec 10;5(3):e1089381. PMID: 27141346.
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
Bachireddy P, et al. Blood. 2014 Feb 27;123(9):1412-21. PMID: 24357730.
|Related PD-1/PD-L1 Products|
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1.
BMS-1001 is a potent PD-1/PD-L1 interaction inhibitor.
Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1.
Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.